110 related articles for article (PubMed ID: 7513496)
1. Increased expression of CD56 and HLA/DR antigens in CD2+ cells from multiple myeloma patients.
Lapeña P; Prieto A; Garcia-Suarez J; Reyes E; San Miguel J; Jorda J; Alvarez-Mon M
Am J Hematol; 1994 Jun; 46(2):158-9. PubMed ID: 7513496
[No Abstract] [Full Text] [Related]
2. Cultured human thymocytes lacking CD2 and CD11a/CD18 antigens are functional and adhere to endothelial cells via CD56 or CDw49d molecules.
Poggi A; Zocchi MR
Cell Immunol; 1992 Apr; 140(2):319-30. PubMed ID: 1371947
[TBL] [Abstract][Full Text] [Related]
3. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity.
Maïza H; Leca G; Mansur IG; Schiavon V; Boumsell L; Bensussan A
J Exp Med; 1993 Sep; 178(3):1121-6. PubMed ID: 7688788
[TBL] [Abstract][Full Text] [Related]
4. Involvement of HLA-DR+ large granular lymphocytes in the induction of tumor necrosis factor by Mycobacterium avium-intracellulare complex.
Michelini-Norris MB; Blanchard DK; Friedman H; Djeu JY
J Leukoc Biol; 1991 Dec; 50(6):529-38. PubMed ID: 1682407
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
Mathew P; Ahmann GJ; Witzig TE; Roche PC; Kyle RA; Greipp PR
Br J Haematol; 1995 Jun; 90(2):459-61. PubMed ID: 7540857
[TBL] [Abstract][Full Text] [Related]
6. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells.
Barker HF; Hamilton MS; Ball J; Drew M; Franklin IM
Br J Haematol; 1992 Jul; 81(3):331-5. PubMed ID: 1382543
[TBL] [Abstract][Full Text] [Related]
7. Leu-19 in myeloma--a new role for an old antibody.
Wetter O; Brandhorst D; Reiter W
Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
[No Abstract] [Full Text] [Related]
8. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation.
Zarcone D; Viale O; Cerruti G; Tenca C; Malorni W; Arancia G; Iosi F; Galandrini R; Velardi A; Moretta A
Cell Immunol; 1992 Sep; 143(2):389-404. PubMed ID: 1380897
[TBL] [Abstract][Full Text] [Related]
9. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma with coexpression of myeloid and natural killer cell antigens.
Drach J; Gattringer C; Huber H
Blood; 1990 Jul; 76(1):265-6. PubMed ID: 1694700
[No Abstract] [Full Text] [Related]
11. TCR-CD56+CD2+ nasal lymphomas with membrane-localized CD3 positivity: are the CD3+ cells neoplastic or reactive?
Tao Q; Chiang AK; Srivastava G; Ho FC
Blood; 1995 May; 85(10):2993-6. PubMed ID: 7537987
[No Abstract] [Full Text] [Related]
12. Changes of blood CD16/CD56 (NK) and HLA-DR/CD3-positive lymphocyte amounts in HIV-infected children, as related to clinical progression and p24-antigen/p24-antibody presence.
Voiculescu C; Avramescu C; Balasoiu M; Turculeanu A; Radu E
FEMS Immunol Med Microbiol; 1994 Sep; 9(3):217-21. PubMed ID: 7529081
[TBL] [Abstract][Full Text] [Related]
13. Distribution of Leu-19(CD56) natural killer lymphocyte antigen in cultured cells from the human embryonic central nervous system.
Aloisi F; Samoggia P; Montesoro E; Testa U; Levi G; Peschle C
Ann N Y Acad Sci; 1992 Apr; 650():317-21. PubMed ID: 1376574
[No Abstract] [Full Text] [Related]
14. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells.
Drach J; Gattringer C; Huber H
Clin Exp Immunol; 1991 Mar; 83(3):418-22. PubMed ID: 1706237
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells.
Altomonte M; Gloghini A; Bertola G; Gasparollo A; Carbone A; Ferrone S; Maio M
Cancer Res; 1993 Jul; 53(14):3343-8. PubMed ID: 7686816
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the Fc mu receptor on human natural killer cells. Interaction with its physiologic ligand, human normal IgM, specificity of binding, and functional effects.
Pricop L; Rabinowich H; Morel PA; Sulica A; Whiteside TL; Herberman RB
J Immunol; 1993 Sep; 151(6):3018-29. PubMed ID: 7690792
[TBL] [Abstract][Full Text] [Related]
17. Phenotypical and functional characterization of the idiotype-positive blood B cells in multiple myeloma.
Bloem AC; Chand MA; van Camp B; Bast EJ; Ballieux RE
Scand J Immunol; 1988 Dec; 28(6):791-9. PubMed ID: 2906758
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-21 differentially affects human natural killer cell subsets.
Wendt K; Wilk E; Buyny S; Schmidt RE; Jacobs R
Immunology; 2007 Dec; 122(4):486-95. PubMed ID: 17635612
[TBL] [Abstract][Full Text] [Related]
19. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures.
Fuchshuber PR; Lotzová E
Lymphokine Cytokine Res; 1992 Oct; 11(5):271-6. PubMed ID: 1281676
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56bright natural killer subpopulation.
Dadmarz R; Bockstoce DC; Golub SH
Lymphokine Cytokine Res; 1994 Dec; 13(6):349-57. PubMed ID: 7535569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
